公开(公告)号：US06987111B2

公开(公告)日：2006-01-17

申请号：US10635232

申请日：2003-08-06

Applicant: Kristyn Greco ,  James Wright

Inventor： Kristyn Greco ,  James Wright

IPC: A61K31/445 ,  A61K31/495

CPC classification number: C07D211/52 ,  A61K31/445

Abstract: The invention relates to the discovery that pamoate salts of haloperidol and aripiprazole result in a good to superior long acting and/or extended release profile. Thus, in one aspect of the invention, the invention includes pamoate salts of haloperidol or aripiprazole. Preferably, the pamoate salt is characterized by a ratio of haloperidol to pamoate of 1:1 or 2:1. The pamoate salt can be crystalline, such as a needle or a dense crystal, such as described in the Figures.The invention further relates to methods of treating an individual in need thereof comprising administering a pharmaceutical composition comprising a pamoate salt of haloperidol and aripiprazole.

Abstract translation: 本发明涉及氟哌啶醇和阿立哌唑的双羟萘酸盐产生优异的长效和/或延长释放特征的发现。 因此，在本发明的一个方面，本发明包括氟哌啶醇或阿立哌唑的双羟萘酸盐。 优选地，双羟萘酸盐的特征在于氟哌啶醇与双羟萘酸的比例为1:1或2:1。 双羟萘酸盐可以是结晶的，例如针或致密晶体，如图中所述。 本发明还涉及治疗有需要的个体的方法，其包括施用包含氟哌啶醇和阿立哌唑的双羟萘酸盐的药物组合物。

公开(公告)号：US20060040922A1

公开(公告)日：2006-02-23

申请号：US11252862

申请日：2005-10-18

Applicant: Kristyn Greco ,  James Wright

Inventor： Kristyn Greco ,  James Wright

IPC: A61K31/551 ,  A61K31/496 ,  A61K31/445

CPC classification number: C07D211/52 ,  A61K31/445

Abstract: The invention relates to the discovery that pamoate salts of haloperidol and aripiprazole result in a good to superior long acting and/or extended release profile. Thus, in one aspect of the invention, the invention includes pamoate salts of haloperidol or aripiprazole. Preferably, the pamoate salt is characterized by a ratio of haloperidol to pamoate of 1:1 or 2:1. The pamoate salt can be crystalline, such as a needle or a dense crystal, such as described in the Figures. The invention further relates to methods of treating an individual in need thereof comprising administering a pharmaceutical composition comprising a pamoate salt of haloperidol and aripiprazole.

公开(公告)号：US20050032836A1

公开(公告)日：2005-02-10

申请号：US10635232

申请日：2003-08-06

Applicant: Kristyn Greco ,  James Wright

Inventor： Kristyn Greco ,  James Wright

IPC: A61K31/445 ,  C07D211/52 ,  C07D211/54

CPC classification number: C07D211/52 ,  A61K31/445

Abstract: The invention relates to the discovery that pamoate salts of haloperidol and aripiprazole result in a good to superior long acting and/or extended release profile. Thus, in one aspect of the invention, the invention includes pamoate salts of haloperidol or aripiprazole. Preferably, the pamoate salt is characterized by a ratio of haloperidol to pamoate of 1:1 or 2:1. The pamoate salt can be crystalline, such as a needle or a dense crystal, such as described in the Figures. The invention further relates to methods of treating an individual in need thereof comprising administering a pharmaceutical composition comprising a pamoate salt of haloperidol and aripiprazole.

Abstract translation: 本发明涉及氟哌啶醇和阿立哌唑的双羟萘酸盐产生优异的长效和/或延长释放特征的发现。 因此，在本发明的一个方面，本发明包括氟哌啶醇或阿立哌唑的双羟萘酸盐。 优选地，双羟萘酸盐的特征在于氟哌啶醇与双羟萘酸的比例为1:1或2:1。 双羟萘酸盐可以是结晶的，例如针或致密晶体，如图中所述。 本发明还涉及治疗有需要的个体的方法，其包括施用包含氟哌啶醇和阿立哌唑的双羟萘酸盐的药物组合物。

公开(公告)号：US07892492B2

公开(公告)日：2011-02-22

申请号：US11635312

申请日：2006-12-07

Applicant: Robin H. Bogner ,  Theodore L. Bergman ,  Kristyn Greco ,  Derek J. Michaels ,  Szymon J. Chawarski

Inventor： Robin H. Bogner ,  Theodore L. Bergman ,  Kristyn Greco ,  Derek J. Michaels ,  Szymon J. Chawarski

IPC: G01N15/06 ,  G01N1/10 ,  B01L3/00 ,  B01L99/00 ,  B01L9/00 ,  B01D11/04 ,  B01D11/02

CPC classification number: G01N21/05 ,  G01N21/0317 ,  G01N21/0332 ,  G01N21/09 ,  G01N21/272 ,  G01N2021/0342 ,  G01N2021/056 ,  G01N2201/0245

Abstract: The present disclosure is directed to an apparatus and method for studying dissolution of a compact sample. The compact sample is typically a pharmaceutical drug sample. A flow-through apparatus includes a frame defining a flow-through channel, a removable insert having a drug sample, the insert positioned within the frame such that a fluid interacts with the sample when the fluid passes through the flow channel. The frame has an opening on the top side to allow a glass plate, typically a microscope cover slip to be positioned within the frame and allow viewing of the fluid flow and interaction with the drug sample. The hydrodynamics of the fluid flow are either known or computed. Thus, dissolution can be studied and observed in view of hydrodynamic characteristics. Typically, only a small amount of sample is necessary for a study. The flow-through apparatus is designed to fit on a microscopy stage and allow visual observation of the fluid/sample interaction.

Abstract translation: 本公开涉及用于研究紧凑样品的溶解的装置和方法。 紧凑型样品通常是药物药物样品。 流通装置包括限定流通通道的框架，具有药物样本的可移除插入件，插入件定位在框架内，使得流体在流体通过流动通道时与样品相互作用。 框架在顶侧具有开口，以允许玻璃板，通常是显微镜盖滑动件定位在框架内，并允许观察流体流动和与药物样品的相互作用。 流体流动的流体动力学是已知的或计算的。 因此，考虑到流体动力特性，可以研究和观察溶解。 通常，研究只需要少量样品。 流通装置设计成适合于显微镜台上，并允许目视观察流体/样品相互作用。

公开(公告)号：US20080138261A1

公开(公告)日：2008-06-12

申请号：US11635312

申请日：2006-12-07

Applicant: Robin H. Bogner ,  Theodore L. Bergman ,  Kristyn Greco ,  Derek J. Michaels ,  Szymon J. Chawarski

Inventor： Robin H. Bogner ,  Theodore L. Bergman ,  Kristyn Greco ,  Derek J. Michaels ,  Szymon J. Chawarski

IPC: B01D11/02

CPC classification number: G01N21/05 ,  G01N21/0317 ,  G01N21/0332 ,  G01N21/09 ,  G01N21/272 ,  G01N2021/0342 ,  G01N2021/056 ,  G01N2201/0245

Abstract: The present disclosure is directed to an apparatus and method for studying dissolution of a compact sample. The compact sample is typically a pharmaceutical drug sample. A flow-through apparatus includes a frame defining a flow-through channel, a removable insert having a drug sample, the insert positioned within the frame such that a fluid interacts with the sample when the fluid passes through the flow channel. The frame has an opening on the top side to allow a glass plate, typically a microscope cover slip to be positioned within the frame and allow viewing of the fluid flow and interaction with the drug sample. The hydrodynamics of the fluid flow are either known or computed. Thus, dissolution can be studied and observed in view of hydrodynamic characteristics. Typically, only a small amount of sample is necessary for a study. The flow-through apparatus is designed to fit on a microscopy stage and allow visual observation of the fluid/sample interaction.

Abstract translation: 本公开涉及用于研究紧凑样品的溶解的装置和方法。 紧凑型样品通常是药物药物样品。 流通装置包括限定流通通道的框架，具有药物样本的可移除插入件，插入件定位在框架内，使得流体在流体通过流动通道时与样品相互作用。 框架在顶侧具有开口，以允许玻璃板，通常是显微镜盖滑动件定位在框架内，并允许观察流体流动和与药物样品的相互作用。 流体流动的流体动力学是已知的或计算的。 因此，考虑到流体动力特性，可以研究和观察溶解。 通常，研究只需要少量样品。 流通装置设计成适合于显微镜台上，并允许目视观察流体/样品相互作用。